J Zhang1, Y Li. 1. The First Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, China. yangli5689@hotmail.com.
Abstract
OBJECTIVE: MicroRNAs has been proved to play vital roles in many biological processes. In the present study, the expression profile of oncogenic miR-155 in the activated antitumor cytotoxic T lymphocytes generated by the fusion of dendritic cells with breast carcinoma cells has been demonstrated. MATERIALS AND METHODS: Expression profile of oncogenic miR-155 was noted in antitumor cytotoxic T lymphocytes, which was generated by the fusion of dendritic cells (DC) with breast carcinoma cells (MCF-7). The fused cells were used to induce and generate antitumor CTL with the standard procedure. Flow cytometry, as well as qPCR analysis, were performed to identify the expression profile of oncogenic miR-155 in the generated antitumor CTL against breast cancer. RESULTS: Compared with controls, the presence of MUC-1 and MHC-II in the DC/MCF-7 fused cells was confirmed by flow cytometry analysis. qPCR experimental results conclude that oncogenic miR-155 level was decreased in the antitumor CTL generated against breast cancer cells. CONCLUSIONS: We observed that the oncogenic miR-155 level was down-regulated in the antitumor CTL against breast cancer, and it may be used as the effective treatment to eliminate the malignant cells in the breast cancer patients.
OBJECTIVE: MicroRNAs has been proved to play vital roles in many biological processes. In the present study, the expression profile of oncogenic miR-155 in the activated antitumor cytotoxic T lymphocytes generated by the fusion of dendritic cells with breast carcinoma cells has been demonstrated. MATERIALS AND METHODS: Expression profile of oncogenic miR-155 was noted in antitumor cytotoxic T lymphocytes, which was generated by the fusion of dendritic cells (DC) with breast carcinoma cells (MCF-7). The fused cells were used to induce and generate antitumor CTL with the standard procedure. Flow cytometry, as well as qPCR analysis, were performed to identify the expression profile of oncogenic miR-155 in the generated antitumor CTL against breast cancer. RESULTS: Compared with controls, the presence of MUC-1 and MHC-II in the DC/MCF-7 fused cells was confirmed by flow cytometry analysis. qPCR experimental results conclude that oncogenic miR-155 level was decreased in the antitumor CTL generated against breast cancer cells. CONCLUSIONS: We observed that the oncogenic miR-155 level was down-regulated in the antitumor CTL against breast cancer, and it may be used as the effective treatment to eliminate the malignant cells in the breast cancerpatients.